Search results for "Immunologic"

showing 10 items of 1115 documents

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

2010

On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia.Treatment-naive, physically fit patients (aged 30-81 years) with CD20-positive chronic lymphocytic leukaemia were randomly assigned in a one-to-one ratio to receive six courses of intravenous fludarabine (25 mg/m(2) per day) and cyclophosphamide (250 mg/m(2) per day) for the first 3 days of each 28-day treatment course with or without rituximab (375 mg/m(2) on day 0 of first course, and 500 mg/m(2) on da…

AdultMalemedicine.medical_specialtyNeutropeniaFCR RegimenKaplan-Meier EstimateOfatumumabSeverity of Illness IndexGastroenterologyDisease-Free SurvivalDrug Administration ScheduleAntibodies Monoclonal Murine-Derivedchemistry.chemical_compoundChemoimmunotherapyObinutuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansImmunologic FactorsMedicineCyclophosphamideAgedAged 80 and overbusiness.industryIncidenceAntibodies MonoclonalLeukopeniaGeneral MedicineMiddle AgedLeukemia Lymphocytic Chronic B-CellSurgeryFludarabineTreatment OutcomechemistryDisease ProgressionFemaleRituximabRefractory Chronic Lymphocytic LeukemiaRituximabbusinessVidarabineUntreated Chronic Lymphocytic Leukemiamedicine.drug
researchProduct

Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study

2016

Background and Aims: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nested case-control study, we aimed to characterise incident cases of cancer in IBD. The role of immunomodulators vs clinical characteristics of IBD as risk factors for cancer was also investigated. Materials and Methods: From January 2012 to December 2014, each IBD patient with incident cancer was matched with two IBD patients without cancer for: IBD type, gender, and age. Risk factors were assessed by multivariate regression analysis. Results: IBD patients considered numbered 44619: 21953 Crohn’s disease \[CD], 22666 ulcerative colitis [UC]. Cancer occurred in 174 patients…

AdultMalemedicine.medical_specialtyPancolitisAdolescentColorectal cancerphenotypeSettore MED/12 - GASTROENTEROLOGIAcancer riskInflammatory bowel disease; cancer risk; phenotype; Adolescent; Adult; Aged; Aged 80 and over; Case-Control Studies; Female; Follow-Up Studies; Humans; Immunologic Factors; Incidence; Inflammatory Bowel Diseases; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms; Prospective Studies; Risk Factors; Young Adult; PhenotypeGastroenterologyInflammatory bowel diseaseInflammatory bowel disease03 medical and health sciencesYoung Adult0302 clinical medicineRisk FactorsInternal medicineNeoplasms80 and overmedicineHumansImmunologic FactorsProspective StudiesRisk factorProspective cohort studyAgedAged 80 and overbusiness.industryIncidenceSettore MED/09 - MEDICINA INTERNAGastroenterologyCancerGeneral MedicineMiddle Agedmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisLogistic Models030220 oncology & carcinogenesisCase-Control StudiesNested case-control studyMultivariate Analysis030211 gastroenterology & hepatologyFemalemedicine.symptombusinessInflammatory bowel disease; cancer risk; phenotypeFollow-Up Studies
researchProduct

Incidence of Narcolepsy in Germany

2015

Study objectives Following the 2009 pandemic, reports of an association between an AS03 adjuvanted H1N1 pandemic influenza vaccine and narcolepsy were published. Besides determining background incidence rates for narcolepsy in Germany this study aimed at investigating whether there was a change in incidence rates of narcolepsy between the pre-pandemic, pandemic, and the post-pandemic period on the population level. Design Retrospective epidemiological study on the incidence of narcolepsy with additional capture-recapture analysis. Setting German sleep centers. Patients or participants Eligible were patients with an initial diagnosis of narcolepsy (ICD10 Code G47.4) within the period from Ja…

AdultMalemedicine.medical_specialtyPediatricsAdolescentInfluenza vaccineRate ratioIncidence of Narcolepsy in GermanyYoung AdultInfluenza A Virus H1N1 SubtypeAdjuvants ImmunologicPhysiology (medical)GermanyEpidemiologyInfluenza HumanmedicineHumansYoung adultChildNarcolepsyRetrospective Studiesbusiness.industryIncidence (epidemiology)IncidenceVaccinationInfant NewbornInfantRetrospective cohort studyGeneral Medicinemedicine.diseaseInfluenza VaccinesChild PreschoolObservational studyFemaleNeurology (clinical)SeasonsbusinessSleepNarcolepsy
researchProduct

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic …

2007

SummaryTreatment of relapsed or refractory autoimmune mediated haemolytic syndromes, such as autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), represents a therapeutic challenge. Here we report on our experience with the monoclonal anti-CD20 antibody rituximab (R) compared to standard treatment in these diseases. Patients with non-familialTTP orAIHA and no underlying malignancy were included in our analysis. Safety and efficacy of R-treatment were compared to results obtained in standard treatment approaches. Altogether, 27 patients were analyzed, comprising 15 patients withTTP and 12 patients with AIHA. The patients’ average age at the time of diagnosis wa…

AdultMalemedicine.medical_specialtyTime FactorsThrombotic thrombocytopenic purpuraSalvage therapyGastroenterologyDisease-Free SurvivalAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRecurrenceMedian follow-upGermanyhemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProgression-free survivalAgedRetrospective StudiesSalvage TherapyPurpura Thrombocytopenic Idiopathicbusiness.industryStandard treatmentAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeDrug Therapy CombinationFemaleRituximabAnemia Hemolytic AutoimmuneRituximabbusinessFollow-Up Studiesmedicine.drugThrombosis and Haemostasis
researchProduct

Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients

2020

Abstract Diagnosis, treatment, and management of invasive mould infections (IMI) are challenged by several risk factors, including local epidemiological characteristics, the emergence of fungal resistance and the innate resistance of emerging pathogens, the use of new immunosuppressants, as well as off-target effects of new oncological drugs. The presence of specific host genetic variants and the patient's immune system status may also influence the establishment of an IMI and the outcome of its therapy. Immunological components can thus be expected to play a pivotal role not only in the risk assessment and diagnosis, but also in the treatment of IMI. Cytokines could improve the reliability…

AdultMalemedicine.medical_specialtyTreatment responseAntifungal Agentshemato-oncological malignanciesAspergillosismucormycosis03 medical and health sciencesImmunocompromised HostImmune systemSDG 3 - Good Health and Well-beingInternal medicineNeoplasmsEpidemiologyimmunological statusmedicineHumansIntensive care medicine030304 developmental biologyAgedAged 80 and over0303 health sciencesHematology030306 microbiologybusiness.industryinvasive pulmonary aspergillosishematologyMucormycosisCancerReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseaseInfectious Diseaseshemato-oncological malignancies; hematology; immunological status; invasive pulmonary aspergillosis; mucormycosisAcademicSubjects/SCI00960FemaleOriginal ArticleRisk assessmentbusinessAcademicSubjects/MED00010Invasive Fungal Infections
researchProduct

Acute Phase Proteins Are Baseline Predictors of Tuberculosis Treatment Failure

2021

Systemic inflammation is a characteristic feature of pulmonary tuberculosis (PTB). Whether systemic inflammation is associated with treatment failure in PTB is not known. Participants, who were newly diagnosed, sputum smear and culture positive individuals with drug-sensitive PTB, were treated with standard anti-tuberculosis treatment and classified as having treatment failure or microbiological cure. The plasma levels of acute phase proteins were assessed at baseline (pre-treatment). Baseline levels of C-reactive protein (CRP), alpha-2 macroglobulin (a2M), Haptoglobin and serum amyloid P (SAP) were significantly higher in treatment failure compared to cured individuals. ROC curve analysis …

AdultMalemedicine.medical_specialtyTuberculosisImmunologyAntitubercular AgentsSystemic inflammationGastroenterologyCohort StudiesInternal medicinemedicineHumansImmunology and AllergyProspective StudiesTreatment FailureTuberculosis PulmonaryOriginal ResearchHaptoglobinsbiologybusiness.industryHaptoglobinAcute-phase proteinArea under the curveRC581-607Middle Agedmedicine.diseasePregnancy-Associated alpha 2-MacroglobulinsMacroglobulinSerum Amyloid P-ComponentC-Reactive ProteintuberculosisROC CurveinflammationTB treatmentacute phase proteinsbiology.proteinbiomarkerSputumBiomarker (medicine)FemaleImmunologic diseases. Allergymedicine.symptombusinessBiomarkersAcute-Phase ProteinsFrontiers in Immunology
researchProduct

Intratympanic Dexamethasone and Hyaluronic Acid in Patients with Low-Frequency and Ménière's-Associated Sudden Sensorineural Hearing Loss

2005

Steroids are widely used for the treatment of cochleovestibular disorders. Direct steroid application in the middle ear cavity, when combined with a round window membrane permeability-modulating substance, increases the level of the steroid reaching the target cells. We measured hearing in patients with idiopathic isolated low-frequency sensorineural hearing loss and in patients with sudden sensorineural hearing loss and a history of Ménière's disease. Contradictory reports about effectiveness of intratympanic steroid therapy on vertigo control and hearing improvement in patients with Ménière's disease exist in the literature.Eighteen patients with isolated low-frequency idiopathic sudden s…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing lossHearing Loss SensorineuralAnti-Inflammatory AgentsInjections IntralesionalAudiologyDexamethasoneAdjuvants ImmunologicVertigootorhinolaryngologic diseasesmedicineHumansProspective StudiesHyaluronic AcidProspective cohort studyMeniere DiseaseDexamethasoneRound windowbiologymedicine.diagnostic_testbusiness.industryAuditory ThresholdHearing Loss SuddenMiddle Agedbiology.organism_classificationmedicine.diseaseSensory SystemsTreatment Outcomemedicine.anatomical_structureOtorhinolaryngologyMiddle earAudiometry Pure-ToneFemaleSensorineural hearing lossNeurology (clinical)medicine.symptomAudiometrybusinessmedicine.drugOtology & Neurotology
researchProduct

Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study

2019

Background: Graves' disease is one of the most common autoimmune conditions, but treatment remains imperfect. This study explores the first-in-human use of antigen-specific immunotherapy with a combination of two thyrotropin receptor (TSHR) peptides (termed ATX-GD-59) in Graves' hyperthyroidism. Methods: Twelve participants (11 female) with previously untreated mild to moderate Graves' hyperthyroidism were enrolled in a Phase I open label trial to receive 10 doses of ATX-GD-59 administered intradermally over an 18-week period. Adverse events, tolerability, changes in serum free thyroid hormones, and TSHR autoantibodies were measured. Results: Ten subjects received all 10 doses of ATX-GD-59,…

AdultMalemedicine.medical_specialtyendocrine systemendocrine system diseasesInjections Intradermalthyroid stimulating hormone receptorEndocrinology Diabetes and Metabolismmedicine.medical_treatmentGraves' diseasedesensitization030209 endocrinology & metabolismDiseaseImmunology Autoimmunity and Graves’ OphthalmopathyimmunomodulationThyrotropin receptor03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinemedicineHumansAdverse effectDesensitization (medicine)business.industryAutoantibodypeptide immunotherapyReceptors ThyrotropinImmunotherapyMiddle Agedmedicine.diseaseGraves' diseaseGraves Disease3. Good healthInjection Site ReactionThyroxineEndocrinologyTreatment OutcomeTolerabilityDesensitization Immunologic030220 oncology & carcinogenesisTriiodothyronineFemaleautoimmune thyroid diseasebusinessPeptidesImmunoglobulins Thyroid-StimulatingThyroid
researchProduct

Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study.

1990

Abstract The influence of ciamexone on the activity and course of endocrine orbitopathy was investigated. Fifty-one patients with active orbitopathy classes II-VI were allocated randomly to two groups: over a period of six months, 26 patients received 300 mg/day ciamexone and 25 patients received placebo tablets. In both groups, prednisolone was administered in addition in the first four weeks. Ophthalmological investigations and clinical tests as well as orbit sonography were carried out before as well as one, three and six months after the beginning of therapy. Before and after treatment, computer tomography of the orbit was performed. Symptoms and signs did not show any significant impro…

AdultMalemedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEye diseasePrednisoloneAziridinesPlacebo-controlled studyVisual AcuityPlaceboRandom AllocationEndocrinologyAdjuvants ImmunologicDouble-Blind MethodInternal medicineOrbital DiseasesMedicineHumansExophthalmusIntraocular PressureAgedChemotherapybiologybusiness.industryThyroiditis AutoimmuneEndocrine orbitopathyGeneral MedicineMiddle Agedbiology.organism_classificationmedicine.diseaseEndocrinologyPrednisoloneCorticosteroidFemalebusinessmedicine.drugActa endocrinologica
researchProduct

[Treatment of sensorineural hearing loss in acute viral otitis media with intratympanic dexamethasone and hyaluronic acid in comparison with intraven…

2006

Background: Intratympanic dexamethasone with hyaluronic acid has shown to be an effective treatment of the inner ear damage in sudden hearing loss and Meniere's disease. It is not known yet if the same applies to the toxic inner ear damage in acute viral otitis media. Patients: Retrospectively, 26 patients who suffered from acute viral otitis media with sensorineural hearing loss were examined with regard to the improvement of their inner ear hearing loss. Twelve patients were treated with intravenous therapy only, consisting of hydroxyethylstarch, pentoxifylline and prednisolone. Fourteen patients additionally received intratympanic injections, consisting of dexamethasone and hyaluronic ac…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHearing Loss SensorineuralPrednisoloneVasodilator AgentsAnti-Inflammatory AgentsEar MiddleDexamethasonePentoxifyllineInjectionsHydroxyethyl Starch DerivativesAdjuvants ImmunologicAudiometryotorhinolaryngologic diseasesmedicineHumansHyaluronic AcidPentoxifyllineInfusions IntravenousDexamethasoneRetrospective StudiesRound windowmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseSurgeryOtitis MediaOtitismedicine.anatomical_structureOtorhinolaryngologyIntravenous therapyAnesthesiaData Interpretation StatisticalAcute DiseasePrednisoloneSensorineural hearing lossDrug Therapy CombinationFemalesense organsmedicine.symptomAudiometrybusinessBone Conductionmedicine.drugLaryngo- rhino- otologie
researchProduct